

**RECEIVED**

MAR 21 2003

DATE: 3-14-03 SHEET 1 of 1

Form PTO - 1449 (Modified)

TECH CENTER 1600/2900FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6752.US.01

SERIAL NO.

09/716,395

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT(S)

S. Fesik, et al.

FILING DATE

11/20/00

GROUP

1642

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

	C1	Tsujimoto, Y. et al., "Analysis of the Structure, Transcripts, and Protein Products of BCL-2, the Gene Involved in Human Follicular Lymphoma," Proceedings of the National Academy of Sciences of USA, Vol. 83, (07/01/86), pages 5214-5218, XP000673572
	C2	Anderson, M. et al., "Refolding, Purification, and Characterization of a Loop Deletion Mutant of Human BCL-2 From Bacterial Inclusion Bodies," Protein Expression and Purification, Vol. 15, No. 2, (03/1999), pages 162-170 XP000927994
	C3	Muchmore, S.W., et al., "X-ray and NMR Structure of Human Bcl-xL, and Inhibitor of Programmed Cell Death," Nature, Vol. 381, (05/23/96), pages 335-341, XP002111426
	C4	Ottillie, S., et al., "Dimerization Properties of Human BAD," Journal of Biological Chemistry, Vol. 272, No. 49, (12/05/97), pages 30866-30872, XP002198263

EXAMINER

DATE CONSIDERED

7/14/2004

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)